 Hydantoin derivatives for treating complications of diabetes |
| OF PREFERRED EMBODIMENTS The invention will now be further explained with reference to M... |
|
| Oral composition |
| OF THE INVENTION Although the present invention is described below with reference to examples, the ... |
|
| Formulation for administration of steroid compounds |
| OF THE INVENTION By 5.beta. steroid is meant .alpha. ET, .beta. ET, and ED. In addition certain ... |
|
| Geldanamycin derivatives and antitumor drug |
| OF THE PREFERRED EMBODIMENTS The Geldanamycin derivatives having the formula (I) can be produced ... |
|
| Method and compositions for inhibiting protein kinases |
| We claim: 1. A method for inhibiting a protein kinase, which comprises: contacting a composition ... |
|
| Identification of drug candidates modulating factor VII-mediated intracellular signaling |
| OF THE INVENTION The present invention relates to the use of FVII or FVIIa or another TF agonist ... |
|
|
Thiolactam-n-acetic acid derivatives
| Details |
Inventors: Meguro, Kanji; Ikeda, Hitoshi; Yamamoto, Yujiro;
Assignee: Takeda Chemical Industries, Ltd. (Osaka, JP); Senju Pharmaceutical Co., Ltd. (Osaka, JP)
Primary Examiner: Raymond; Richard L.
Assistant Examiner:
Attorney, Agent or Firm: Wenderoth, Lind & Ponack
Compounds of the general formula: ##STR1## wherein, R.sup.1 and R.sup.2 are, the same or different, hydrogen, a halogen, a lower alkyl, a cycloalkyl, a lower alkoxy, trifluoromethyl or a phenylalkyloxy whose phenyl ring may be substituted by one to three substituents selected from the group consisting of a halogen, a lower alkyl, a lower alkoxy, methylenedioxy and trifluoromethyl; R.sup.3 is hydrogen or methyl; R.sup.4 is carboxyl or an esterified carboxyl; and X is oxygen or sulfur, or a salt thereof. These compounds possess aldose reductase inhibitory and platelet aggregation inhibitory activities, and are of use as drugs for prevention and treatment of diabetic complications such as diabetic cataract, retinophathy, nephropathy, and neuropathy. |
|
DETAILED DESCRIPTION We claim: 1.
A compound of the formula: ##STR11## wherein, R.
sup.
1 and R.
sup.
2 are, the same or different, hydrogen, a halogen, a lower alkyl, a cycloalkyl having 3.
degree.
-7 carbon atoms, a lower alkoxy, trifluoromethyl or a phenylalkoxy having 7-9 carbon atoms whose phenyl ring may be substituted by one or three substituents selected from the group consisting of a halogen, a lower alkyl, a lower alkoxy, methylenedioxy and trifluoromethyl; R.
sup.
3 is hydrogen or methyl; R.
sup.
4 is carboxyl or an esterified carboxyl; and X is oxygen or sulfur, or a pharmaceutically acceptable salt thereof.
2.
A compound as claimed in claim 1, wherein X is oxygen.
3.
A compound as claimed in claim 1, wherein one of R.
sup.
1 and R.
sup.
2 is hydrogen and the other is a lower alkyl.
4.
A compound as claimed in claim 1, wherein the compound is 8-ethyl-3,4-dihydro-2-isopropyl-3-thioxo-2H-1,4-benzoxazine-4-acetic acid.
5.
A compound as claimed in claim 1, wherein the compound is 3,4-dihydro-2,8-diisopropyl-3-thioxo-2H-1,4-benzoxazine-4-acetic acid.
6.
A compound as claimed in claim 1, wherein the compound is 8-t-butyl-3,4-dihydro-2-isopropyl-3- thioxo-2H-1,4-benzoxazine-4-acetic acid.
7.
A compound as claimed in claim 1, wherein the compound is 8-cyclohexyl-3,4-dihydro-2-isopropyl-3-thioxo-2H-1,4-benzoxazine-4-acetic acid.
8.
A therapeutic agent for prevention and treatment of diabetic complication, which comprises, as an active ingredient, an effective amount of a compound of the formula: ##STR12## wherein R.
sup.
1 and R.
sup.
2 are, the same or different, hydrogen, a halogen, a lower alkyl, a cycloalkyl having 3-7 carbon atoms, a lower alkoxy, trifluormethyl or a phenylalkoxy having 7-9 carbon atoms whose phenyl ring may be substituted by one to three substituents selected from the group consisting of a halogen, a lower alkyl, a lower alkoxy, methylenedioxy and trifluoromethyl; R.
sup.
3 is hydrogen or methyl; R.
sup.
4 is carboxyl or an esterified carboxyl; and X is oxygen or sulfur, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient therefor
|
| Related patents |
|
|
Rhodanine derivatives, process for their preparation, and aldose reductase inhibitor containing the rhodanine derivatives as active ingredient
I claim: 1. A rhodanine derivative represented by the general formula: ##STR13## wherein R.sup.11 represents a hydrogen atom; R.sup.22 represents: (1) a 5- to 10-...
|
|
|
Fuel supply systems
We claim: 1. A liquid fuel pump arrangement for delivering liquid fuel to an engine comprising a liquid-ring pump including a motor-driven bladed impeller rotor which is ...
|
|
|
Heterocyclic oxophthalazinyl acetic acids
OF THE INVENTION The numbering system of the compounds of formula I is as shown: ##STR5## The term "(C.sub.1 -C.sub.4)alkyl" whenever used in the definitions of R.sub.1 ...
|
|
|
Spiro-isoquinoline-pyrrolidines and analogs thereof useful as aldose reductase inhibitors
We claim: 1. The compounds of structural formula (I) ##STR5## wherein R.sup.1 and R.sup.2 are independently hydrogen, alkyl containining 1 to 6 carbon atoms, halogen, ...
|
|
|
Novel alpha-glucosidase inhibitor, pradimicin Q
OF THE INVENTION One aspect of the present invention provides the compound pradimicin Q and its pharmaceutically acceptable base salts. "Pharmaceutically acceptable ...
|
|
|
.alpha.-glucosidase inhibitors
What is claimed is: 1. 1-deoxy nojirimycin derivatives of the formula ##STR5## and the pharmaceutically acceptable acid addition salts thereof wherein n is zero, 1 or 2 ...
|
|
|
Oxetanones
OF THE INVENTION As used herein, the term "alkyl" denotes a straight or branched chain alkyl containing the number of carbon atoms designated. Examples of C.sub.1 -C....
|
|
|
Process for the preparation of .alpha.-glucosidase inhibitor, pradimicin Q
OF THE INVENTION One aspect of the present invention provides the compound pradimicin Q and its pharmaceutically acceptable base salts. "Pharmaceutically acceptable ...
|
|
|
Pyridopyrimidine derivatives, pharmaceutical compositions containing them and process for preparing same
We claim: 1. A compound of the Formula (I) ##STR7## wherein R is a C.sub.1 to C.sub.12 alkyl group substituted by C.sub.1 to C.sub.4 alkoxycarbonyl, a C.sub.3 to C.sub.9 ...
|
|
|
Inhibitor of absorption of digestion product of food and drink
OF THE INVENTION The following examples are to explain this invention in detail, not to limit its scope. EXAMPLE 1 Acqueous Enteric Material--Flocculant (a) Granules of ...
|
|
|
Weight Loss and Supplements 
